TILRAY BRANDS INC (TLRY.CA) Stock Fundamental Analysis
TSX:TLRY - Toronto Stock Exchange - US88688T1007 - Common Stock - Currency: CAD
TLRY gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. The financial health of TLRY is average, but there are quite some concerns on its profitability. While showing a medium growth rate, TLRY is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
TLRY had negative earnings in the past year.
In the past year TLRY has reported a negative cash flow from operations.
In the past 5 years TLRY always reported negative net income.
In the past 5 years TLRY reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of TLRY (-5.94%) is comparable to the rest of the industry.
TLRY's Return On Equity of -7.17% is fine compared to the rest of the industry. TLRY outperforms 60.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.94% | ||
| ROE | -7.17% | ||
| ROIC | N/A |
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 30.47%, TLRY is in line with its industry, outperforming 48.48% of the companies in the same industry.
TLRY's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for TLRY so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.47% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
2. Health
2.1 Basic Checks
TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
TLRY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TLRY has been increased compared to 5 years ago.
The debt/assets ratio for TLRY has been reduced compared to a year ago.
2.2 Solvency
TLRY has an Altman-Z score of 0.05. This is a bad value and indicates that TLRY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.05, TLRY is in line with its industry, outperforming 57.58% of the companies in the same industry.
A Debt/Equity ratio of 0.10 indicates that TLRY is not too dependend on debt financing.
The Debt to Equity ratio of TLRY (0.10) is better than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.05 |
ROIC/WACCN/A
WACC8.96%
2.3 Liquidity
TLRY has a Current Ratio of 2.54. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.54, TLRY is doing good in the industry, outperforming 69.70% of the companies in the same industry.
TLRY has a Quick Ratio of 1.58. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.58, TLRY perfoms like the industry average, outperforming 57.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.54 | ||
| Quick Ratio | 1.58 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 86.05% over the past year.
TLRY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.38%.
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 78.86% yearly.
EPS 1Y (TTM)86.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.12%
Revenue 1Y (TTM)18.38%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%8.87%
3.2 Future
Based on estimates for the next years, TLRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.07% on average per year.
TLRY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.58% yearly.
EPS Next Y40.17%
EPS Next 2Y31.17%
EPS Next 3Y24.74%
EPS Next 5Y18.07%
Revenue Next Year14.2%
Revenue Next 2Y9.83%
Revenue Next 3Y8.35%
Revenue Next 5Y7.58%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
TLRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
TLRY's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. TLRY is cheaper than 60.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 32.98 |
4.3 Compensation for Growth
TLRY's earnings are expected to grow with 24.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.17%
EPS Next 3Y24.74%
5. Dividend
5.1 Amount
No dividends for TLRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:TLRY (2/21/2025, 7:00:00 PM)
1.35
+0.12 (+9.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners11.8%
Inst Owner ChangeN/A
Ins Owners0.29%
Ins Owner ChangeN/A
Market Cap1.27B
Analysts71.58
Price Target2.81 (108.15%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-77.02%
Min EPS beat(2)-145.1%
Max EPS beat(2)-8.93%
EPS beat(4)0
Avg EPS beat(4)-91.89%
Min EPS beat(4)-145.1%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-435.3%
EPS beat(12)2
Avg EPS beat(12)-369.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.61%
Min Revenue beat(2)-10.57%
Max Revenue beat(2)-4.66%
Revenue beat(4)0
Avg Revenue beat(4)-5.74%
Min Revenue beat(4)-10.57%
Max Revenue beat(4)-0.75%
Revenue beat(8)1
Avg Revenue beat(8)-1.66%
Revenue beat(12)1
Avg Revenue beat(12)-2.67%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.74%
PT rev (3m)-12.65%
EPS NQ rev (1m)8.32%
EPS NQ rev (3m)18.51%
EPS NY rev (1m)-75.95%
EPS NY rev (3m)-83.01%
Revenue NQ rev (1m)-3.24%
Revenue NQ rev (3m)7.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.08 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.26 | ||
| P/tB | 1.47 | ||
| EV/EBITDA | 32.98 |
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS1.26
BVpS5.26
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.94% | ||
| ROE | -7.17% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.47% | ||
| FCFM | N/A |
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
F-Score6
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 12.11 | ||
| Cap/Depr | 24.08% | ||
| Cap/Sales | 3.79% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.54 | ||
| Quick Ratio | 1.58 | ||
| Altman-Z | 0.05 |
F-Score6
WACC8.96%
ROIC/WACCN/A
Cap/Depr(3y)20.35%
Cap/Depr(5y)159.29%
Cap/Sales(3y)4.15%
Cap/Sales(5y)16.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.12%
EPS Next Y40.17%
EPS Next 2Y31.17%
EPS Next 3Y24.74%
EPS Next 5Y18.07%
Revenue 1Y (TTM)18.38%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%8.87%
Revenue Next Year14.2%
Revenue Next 2Y9.83%
Revenue Next 3Y8.35%
Revenue Next 5Y7.58%
EBIT growth 1Y38.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.21%
EBIT Next 3Y37.41%
EBIT Next 5Y24.25%
FCF growth 1Y9.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.73%
OCF growth 3YN/A
OCF growth 5YN/A